| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| María Elena Díaz-Casado, Pilar González-García, Sergio López-Herrador, Agustín Hidalgo-Gutiérrez, Laura Jiménez-Sánchez, Eliana Barriocanal-Casado, Mohammed Bakkali, Chris H A van de Lest, Julia Corral-Sarasa, Esther A Zaal, Celia R Berkers, Luis C Lópe. Oral β-RA induces metabolic rewiring leading to the rescue of diet-induced obesity. Biochimica et biophysica acta. Molecular basis of disease. 2024-06-08. PMID:38851305. |
consequently, β-ra mitigates wat hypertrophy, prevents hepatic steatosis, counteracts metabolic abnormalities in wat and liver, and enhances glucose homeostasis by reducing the insulin/glucagon ratio and plasma levels of gastric inhibitory peptide (gip). |
2024-06-08 |
2024-06-11 |
mouse |
| Munenori Hiromura, Yusaku Mori, Michishige Terasaki, Hideki Kushima, Tomomi Saito, Naoya Osaka, Hironori Yashima, Makoto Ohara, Tomoyasu Fukui, Takanori Matsui, Sho-Ichi Yamagish. Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2. Diabetes & vascular disease research. vol 18. issue 2. 2022-01-11. PMID:35012372. |
we investigated here whether and how gip attenuated cardiac hypertrophy and fibrosis in diabetic mice with obesity. |
2022-01-11 |
2023-08-13 |
mouse |
| Munenori Hiromura, Yusaku Mori, Michishige Terasaki, Hideki Kushima, Tomomi Saito, Naoya Osaka, Hironori Yashima, Makoto Ohara, Tomoyasu Fukui, Takanori Matsui, Sho-Ichi Yamagish. Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2. Diabetes & vascular disease research. vol 18. issue 2. 2022-01-11. PMID:35012372. |
our present findings suggest that gip could inhibit cardiac hypertrophy and fibrosis in diabetic mice via suppression of tgf-β2. |
2022-01-11 |
2023-08-13 |
mouse |
| J De Toro-Martín, E Fernández-Millán, E Lizárraga-Mollinedo, E López-Oliva, P Serradas, F Escrivá, C Alvare. Predominant role of GIP in the development of a metabolic syndrome-like phenotype in female Wistar rats submitted to forced catch-up growth. Endocrinology. vol 155. issue 10. 2015-01-05. PMID:25032669. |
administration of the gip receptor antagonist (pro3)gip to uhf female rats over 21 days markedly reduced visceral fat mass and adipocyte hypertrophy without variations in food intake or body weight. |
2015-01-05 |
2023-08-13 |
rat |
| Victor A Gault, Nigel Irwin, Brian D Green, Jane T McCluskey, Brett Greer, Clifford J Bailey, Patrick Harriott, Finbarr P M O'harte, Peter R Flat. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. vol 54. issue 8. 2005-10-20. PMID:16046312. |
daily injection of (pro3)gip reduced pancreatic insulin content (1.3-fold; p < 0.05) and partially corrected the obesity-related islet hypertrophy and beta-cell hyperplasia of ob/ob mice. |
2005-10-20 |
2023-08-12 |
mouse |
| A Faulkner, P A Marti. Changes in the concentrations of glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide during the lactation cycle in goats. The Journal of dairy research. vol 65. issue 3. 1998-09-10. PMID:9718496. |
changes in gip concentrations mirrored reported changes in the hypertrophy and atrophy of the intestine in ruminants while glp concentrations may be more dependent on the neural and endocrine factors associated with lactation. |
1998-09-10 |
2023-08-12 |
Not clear |